Amgen’s Xgeva received European Commission approval April 3 to treat patients with multiple myeloma, following a similar decision from the U.S. Food and Drug Administration in January. The approval of the drug, which prevents bone degeneration, uses data from a phase 3 study of skeletal-related events in multiple myeloma patients, the largest such international study…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
